Agenus Inc (AGEN) 5.65 $AGEN
Antigenics Up 33.7% Since SmarTrend Uptrend Call (AGEN)
Comtex SmarTrend(R) - Fri Jul 29, 1:21PM CDT
SmarTrend identified an Uptrend for Antigenics (NASDAQ:AGEN) on May 31st, 2016 at $4.18. In approximately 2 months, Antigenics has returned 33.65% as of today's recent price of $5.58.
AGEN: 5.65 (+0.10)
Agenus (AGEN) Posts Narrower than Expected Loss in Q2
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:47AM CDT
Agenus (AGEN) reported first-quarter 2016 loss of 24 cents per share, narrower than the Zacks Consensus Estimate of a loss of 34 cents.
AGEN: 5.65 (+0.10), ANIP: 61.06 (+0.46), MRK: 58.66 (unch), NKTR: 17.76 (+0.47)
Agenus (AGEN) Reports Narrower-than-Expected Q2 Loss
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 9:43AM CDT
Agenus (AGEN) reported a loss of 24 cents in second-quarter of 2016, lower than the Zacks Consensus Estimate of 34 cents.
AGEN: 5.65 (+0.10)
Agenus Reports Second Quarter 2016 Financial Results and Operational Progress
BusinessWire - Thu Jul 28, 7:49AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company developing antibodies, including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today provided a corporate update and reported financial results for the second quarter ended June 30, 2016.
AGEN: 5.65 (+0.10)
Watch for Drug Stocks Earnings on Jul 28: BMY, CELG & More
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 8:47AM CDT
How will drug stocks Bristol-Myers, Celgene and others perform when they report Q2 results on Jul 28, before the opening bell?
AGEN: 5.65 (+0.10), BIIB: 304.00 (+2.17), ABT: 45.29 (unch), JNJ: 125.48 (+0.08), GILD: 80.69 (+0.23), ALXN: 133.50 (+4.90), ARIA: 9.68 (-0.03), BMY: 76.50 (+0.31), CELG: 114.80 (+0.11), NVS: 83.28 (+0.21)
Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-GITR Checkpoint Antibody INCAGN1876 in Patients with Solid Tumors
BusinessWire - Wed Jun 22, 7:50AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today announced that the first patient has been dosed in a Phase 1/2 clinical trial of the anti-GITR agonist antibody INCAGN1876. The trial is being conducted by, and in collaboration with, Incyte Corporation.
AGEN: 5.65 (+0.10)
Agenus to Present at the 2016 JMP Securities Life Sciences Conference
BusinessWire - Wed Jun 15, 7:50AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today announced that Robert B. Stein, M.D., Ph.D., President, Research & Development, will present at the 2016 JMP Securities Life Sciences Conference on Wednesday, June 22nd at 3:30 p.m. ET. The conference will take place at the St. Regis New York in New York City.
AGEN: 5.65 (+0.10)
Agenus Announces Lead Product Candidate Selection in its Collaboration with Merck
BusinessWire - Thu Jun 09, 7:50AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators (CPMs) and cancer vaccines, today announced the selection of a lead product candidate under its license and research collaboration with Merck. Merck, known as MSD outside the United States and Canada, has selected a lead antibody candidate and several backup antibodies, discovered by Agenus, to an undisclosed Merck checkpoint target. Based on this milestone and under the terms of the agreement, Agenus received a $2 million milestone payment from Merck.
AGEN: 5.65 (+0.10), MRK: 58.66 (unch)
Agenus to Webcast Annual Meeting of Stockholders
BusinessWire - Wed Jun 08, 7:50AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, invites investors and the general public to its Annual Meeting of Stockholders to begin at 5:00 p.m. ET on Tuesday, June 14, 2016. The meeting will be held at the Company's headquarters located at 3 Forbes Road, Lexington, MA 02421. Registration for attendees starts at 4:30 p.m. ET.
AGEN: 5.65 (+0.10)
Agenus to Present at the Jefferies 2016 Healthcare Conference
BusinessWire - Thu Jun 02, 7:50AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today announced that Garo H. Armen, Ph.D., Chairman and CEO, and Robert B. Stein, M.D., Ph.D., President, Research & Development, will present a corporate overview at the Jefferies 2016 Healthcare Conference in New York City on Thursday, June 9th at 9:30am ET.
AGEN: 5.65 (+0.10)
Agenus Appoints Ulf Wiinberg to Board of Directors
BusinessWire - Thu May 19, 7:50AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today announced the appointment of Ulf Wiinberg to the Company's Board of Directors. Ulf has more than 30 years of pharmaceutical experience and currently serves on the boards of multiple global drug development companies.
AGEN: 5.65 (+0.10)
Agenus' (AGEN) Q1 Loss Wider than Expected, Revenue Miss
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 10:41AM CDT
Agenus (AGEN) reported first-quarter 2016 loss of 37 cents per share, wider than the Zacks Consensus Estimate of a loss of 23 cents.
AGEN: 5.65 (+0.10), EBS: 30.97 (-2.42), AEGR: 1.47 (+0.03), GSK: 45.67 (+0.42)
Agenus (AGEN) Reports Wider-than-Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 9:41AM CDT
Agenus (AGEN) reported wider-than-expected first quarter loss of 37 cents per share.
AGEN: 5.65 (+0.10)
Agenus reports 1Q loss
Automated Insights - Thu Apr 28, 7:56AM CDT
LEXINGTON, Mass. (AP) _ Agenus Inc. (AGEN) on Thursday reported a loss of $31.8 million in its first quarter.
AGEN: 5.65 (+0.10)
Agenus Reports First Quarter 2016 Financial Results and Operational Progress
BusinessWire - Thu Apr 28, 7:50AM CDT
Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company developing checkpoint antibodies and cancer vaccines, today provided a corporate update and reported financial results for the first quarter ended March 31, 2016.
AGEN: 5.65 (+0.10)
Drug Stocks' Earnings Previews: KERX, BXLT, BMRN, AGEN, IMGN
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 11:10AM CDT
With the first-quarter earnings season in full swing, investors are possibly seeing a ray of hope, as results reported so far have not been as dismal as expected.
AGEN: 5.65 (+0.10), BIIB: 304.00 (+2.17), JNJ: 125.48 (+0.08), BMRN: 100.25 (+0.83), SHPG: 201.65 (+7.65), IMGN: 2.96 (+0.18), BXLT: 46.02 (-0.18), KERX: 4.61 (-0.11), NVS: 83.28 (+0.21)
Agenus Commences Phase 1 Clinical Trial of its CTLA-4 Checkpoint Antibody to Treat Solid Tumors
BusinessWire - Wed Apr 27, 7:50AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing checkpoint antibodies and cancer vaccines, today announced that the first patient has been dosed in the company's Phase 1 clinical trial of AGEN1884, an anti-CTLA-4 checkpoint (CPM) antibody. The open-label, multicenter trial in patients with advanced or refractory cancer is designed to evaluate the safety of AGEN1884 and determine the estimated maximum tolerated dose.
AGEN: 5.65 (+0.10)
Agenus to Report First Quarter 2016 Financial Results on April 28, 2016; Conference Call to Follow
BusinessWire - Thu Apr 21, 6:00AM CDT
Agenus Inc. (NASDAQ: AGEN) will release its first quarter 2016 financial results before the market opens on Thursday, April 28, 2016. Agenus executives will host a conference call at 11 a.m. Eastern Time the same day.
AGEN: 5.65 (+0.10)
Agenus Presents Posters on Checkpoint Antibody Product Candidates at the American Association for Cancer Research (AACR) 2016 Annual Meeting
BusinessWire - Mon Apr 18, 9:30AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing checkpoint modulator antibodies and cancer vaccines, today announced that three abstracts on the Company's checkpoint modulator product candidates were accepted for poster presentations at the American Association for Cancer Research (AACR) 2016 Annual Meeting. The conference is taking place in New Orleans from April 16-20, 2016.
AGEN: 5.65 (+0.10)
The Last Time This Company Made A FDA Submission It Ran 2,100%-- Here's Why You Should Be Looking At It Right Now
ACCESSWIRE - Wed Mar 30, 6:00AM CDT
WINDSOR, ON / ACCESSWIRE / March 30, 2016 / The Wealthy Biotech Trader (or "WBT"
, an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known, biotech, pharma and medical device stocks making news and subsequent market moves, would like to highlight that the maximum gains are made by investors who seek out promising pharma companies before their filing of FDA approval.
AGEN: 5.65 (+0.10), ARGS: 5.31 (+0.05)
Antigenics Up 33.7% Since SmarTrend Uptrend Call (AGEN)
Comtex SmarTrend(R) - Fri Jul 29, 1:21PM CDT
SmarTrend identified an Uptrend for Antigenics (NASDAQ:AGEN) on May 31st, 2016 at $4.18. In approximately 2 months, Antigenics has returned 33.65% as of today's recent price of $5.58.
AGEN: 5.65 (+0.10)
Agenus (AGEN) Posts Narrower than Expected Loss in Q2
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:47AM CDT
Agenus (AGEN) reported first-quarter 2016 loss of 24 cents per share, narrower than the Zacks Consensus Estimate of a loss of 34 cents.
AGEN: 5.65 (+0.10), ANIP: 61.06 (+0.46), MRK: 58.66 (unch), NKTR: 17.76 (+0.47)
Agenus (AGEN) Reports Narrower-than-Expected Q2 Loss
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 9:43AM CDT
Agenus (AGEN) reported a loss of 24 cents in second-quarter of 2016, lower than the Zacks Consensus Estimate of 34 cents.
AGEN: 5.65 (+0.10)
Agenus Reports Second Quarter 2016 Financial Results and Operational Progress
BusinessWire - Thu Jul 28, 7:49AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company developing antibodies, including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today provided a corporate update and reported financial results for the second quarter ended June 30, 2016.
AGEN: 5.65 (+0.10)
Watch for Drug Stocks Earnings on Jul 28: BMY, CELG & More
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 8:47AM CDT
How will drug stocks Bristol-Myers, Celgene and others perform when they report Q2 results on Jul 28, before the opening bell?
AGEN: 5.65 (+0.10), BIIB: 304.00 (+2.17), ABT: 45.29 (unch), JNJ: 125.48 (+0.08), GILD: 80.69 (+0.23), ALXN: 133.50 (+4.90), ARIA: 9.68 (-0.03), BMY: 76.50 (+0.31), CELG: 114.80 (+0.11), NVS: 83.28 (+0.21)
Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-GITR Checkpoint Antibody INCAGN1876 in Patients with Solid Tumors
BusinessWire - Wed Jun 22, 7:50AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today announced that the first patient has been dosed in a Phase 1/2 clinical trial of the anti-GITR agonist antibody INCAGN1876. The trial is being conducted by, and in collaboration with, Incyte Corporation.
AGEN: 5.65 (+0.10)
Agenus to Present at the 2016 JMP Securities Life Sciences Conference
BusinessWire - Wed Jun 15, 7:50AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today announced that Robert B. Stein, M.D., Ph.D., President, Research & Development, will present at the 2016 JMP Securities Life Sciences Conference on Wednesday, June 22nd at 3:30 p.m. ET. The conference will take place at the St. Regis New York in New York City.
AGEN: 5.65 (+0.10)
Agenus Announces Lead Product Candidate Selection in its Collaboration with Merck
BusinessWire - Thu Jun 09, 7:50AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators (CPMs) and cancer vaccines, today announced the selection of a lead product candidate under its license and research collaboration with Merck. Merck, known as MSD outside the United States and Canada, has selected a lead antibody candidate and several backup antibodies, discovered by Agenus, to an undisclosed Merck checkpoint target. Based on this milestone and under the terms of the agreement, Agenus received a $2 million milestone payment from Merck.
AGEN: 5.65 (+0.10), MRK: 58.66 (unch)
Agenus to Webcast Annual Meeting of Stockholders
BusinessWire - Wed Jun 08, 7:50AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, invites investors and the general public to its Annual Meeting of Stockholders to begin at 5:00 p.m. ET on Tuesday, June 14, 2016. The meeting will be held at the Company's headquarters located at 3 Forbes Road, Lexington, MA 02421. Registration for attendees starts at 4:30 p.m. ET.
AGEN: 5.65 (+0.10)
Agenus to Present at the Jefferies 2016 Healthcare Conference
BusinessWire - Thu Jun 02, 7:50AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today announced that Garo H. Armen, Ph.D., Chairman and CEO, and Robert B. Stein, M.D., Ph.D., President, Research & Development, will present a corporate overview at the Jefferies 2016 Healthcare Conference in New York City on Thursday, June 9th at 9:30am ET.
AGEN: 5.65 (+0.10)
Agenus Appoints Ulf Wiinberg to Board of Directors
BusinessWire - Thu May 19, 7:50AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today announced the appointment of Ulf Wiinberg to the Company's Board of Directors. Ulf has more than 30 years of pharmaceutical experience and currently serves on the boards of multiple global drug development companies.
AGEN: 5.65 (+0.10)
Agenus' (AGEN) Q1 Loss Wider than Expected, Revenue Miss
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 10:41AM CDT
Agenus (AGEN) reported first-quarter 2016 loss of 37 cents per share, wider than the Zacks Consensus Estimate of a loss of 23 cents.
AGEN: 5.65 (+0.10), EBS: 30.97 (-2.42), AEGR: 1.47 (+0.03), GSK: 45.67 (+0.42)
Agenus (AGEN) Reports Wider-than-Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 9:41AM CDT
Agenus (AGEN) reported wider-than-expected first quarter loss of 37 cents per share.
AGEN: 5.65 (+0.10)
Agenus reports 1Q loss
Automated Insights - Thu Apr 28, 7:56AM CDT
LEXINGTON, Mass. (AP) _ Agenus Inc. (AGEN) on Thursday reported a loss of $31.8 million in its first quarter.
AGEN: 5.65 (+0.10)
Agenus Reports First Quarter 2016 Financial Results and Operational Progress
BusinessWire - Thu Apr 28, 7:50AM CDT
Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company developing checkpoint antibodies and cancer vaccines, today provided a corporate update and reported financial results for the first quarter ended March 31, 2016.
AGEN: 5.65 (+0.10)
Drug Stocks' Earnings Previews: KERX, BXLT, BMRN, AGEN, IMGN
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 11:10AM CDT
With the first-quarter earnings season in full swing, investors are possibly seeing a ray of hope, as results reported so far have not been as dismal as expected.
AGEN: 5.65 (+0.10), BIIB: 304.00 (+2.17), JNJ: 125.48 (+0.08), BMRN: 100.25 (+0.83), SHPG: 201.65 (+7.65), IMGN: 2.96 (+0.18), BXLT: 46.02 (-0.18), KERX: 4.61 (-0.11), NVS: 83.28 (+0.21)
Agenus Commences Phase 1 Clinical Trial of its CTLA-4 Checkpoint Antibody to Treat Solid Tumors
BusinessWire - Wed Apr 27, 7:50AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing checkpoint antibodies and cancer vaccines, today announced that the first patient has been dosed in the company's Phase 1 clinical trial of AGEN1884, an anti-CTLA-4 checkpoint (CPM) antibody. The open-label, multicenter trial in patients with advanced or refractory cancer is designed to evaluate the safety of AGEN1884 and determine the estimated maximum tolerated dose.
AGEN: 5.65 (+0.10)
Agenus to Report First Quarter 2016 Financial Results on April 28, 2016; Conference Call to Follow
BusinessWire - Thu Apr 21, 6:00AM CDT
Agenus Inc. (NASDAQ: AGEN) will release its first quarter 2016 financial results before the market opens on Thursday, April 28, 2016. Agenus executives will host a conference call at 11 a.m. Eastern Time the same day.
AGEN: 5.65 (+0.10)
Agenus Presents Posters on Checkpoint Antibody Product Candidates at the American Association for Cancer Research (AACR) 2016 Annual Meeting
BusinessWire - Mon Apr 18, 9:30AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing checkpoint modulator antibodies and cancer vaccines, today announced that three abstracts on the Company's checkpoint modulator product candidates were accepted for poster presentations at the American Association for Cancer Research (AACR) 2016 Annual Meeting. The conference is taking place in New Orleans from April 16-20, 2016.
AGEN: 5.65 (+0.10)
The Last Time This Company Made A FDA Submission It Ran 2,100%-- Here's Why You Should Be Looking At It Right Now
ACCESSWIRE - Wed Mar 30, 6:00AM CDT
WINDSOR, ON / ACCESSWIRE / March 30, 2016 / The Wealthy Biotech Trader (or "WBT"
, an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known, biotech, pharma and medical device stocks making news and subsequent market moves, would like to highlight that the maximum gains are made by investors who seek out promising pharma companies before their filing of FDA approval. AGEN: 5.65 (+0.10), ARGS: 5.31 (+0.05)
